Description | The firm helped Pfizer, the pharmaceutical company, protect its $300m-a-year revenue stream from the drug Lyrica in the UK by ensuring that the NHS continued to prescribe Lyrica rather than generic alternatives, for neuropathic pain. The case is significant for other owners of second-use patents. Commended: Nicola Dagg. |